# GlaxoSmithKline: Phase 2 study closed enrollment, 168 enrolled (Respiratory Syncytial Virus Infections)

**Score:** 75/100

| Field | Value |
|---|---|
| Sponsor | GlaxoSmithKline |
| Sponsor type | Industry (pharma, biotech, medtech) |
| Study | A Study Evaluating Persistence of the Immune Response of the Adjuvanted Respiratory Syncytial Virus (RSV) Vaccine and the Safety and Immune Response Following Revaccination in Adults 18 Years of Age and Above Who Received Lung or Kidney Transplant |
| NCT ID | NCT07092865 |
| Phase | Phase 2 |
| Status | active not recruiting |
| Conditions | Respiratory Syncytial Virus Infections |
| Intervention types | biological |
| Target enrollment | 168 |
| Site countries | United States, Australia, Canada, Germany, Italy, Japan, South Korea, Spain |
| Posted | 2025-07-30 |
| Planned start | 2025-08-06 |
| Event | Enrollment closed (active, not recruiting) |
| Event date | 2026-09-28 |
| Last update posted | 2026-09-28 |

## Why this score
- Industry sponsor (buys outsourced services).
- Enrollment closed: data management, monitoring and closeout ahead.
- Phase 2: multi-site, larger budget.
- 168 participants planned.

Source: ClinicalTrials.gov (U.S. National Library of Medicine) API v2 (https://clinicaltrials.gov/study/NCT07092865). Last refreshed: 2026-11-04T06:04:38.232Z.
From public ClinicalTrials.gov registrations. Sponsor and study level only: we never list investigators, contacts or participants. A registration describes a planned study and can change. Status changes are read from each study's current status, actual dates and latest posted update, not a full change history, so an update can be a correction rather than a new change. Verify on ClinicalTrials.gov.